Posted December 07, 2020
RESEARCH TRIANGLE PARK – KBI Biopharma, a contract drug development and manufacturing company with operations in Durham, will establish a new manufacturing facility near Research Triangle Park that will employ more than 200 people in operations and quality assurance.
KBI will co-invest $150 million in the project with an undisclosed pharmaceutical client to support manufacturing of the client’s therapeutic proteins. The 140,000-square-foot facility should be operational by the first quarter of 2022, according to a company news release.
“Expansion of our U.S.-based cell culture operations is a key investment to support our client’s commercialization strategies,” said KBI President and CEO Dirk Lange. “This state-of-the-art facility will leverage the latest innovation in automation and digitalization to best meet the needs for our clients.”
The expansion is the latest growth spurt for KBI, which originated as a spinout of Atlanta life sciences company Kinetic Biosystems and located in Durham in 2003 with the help of a $1 million startup loan from the North Carolina Biotechnology Center. KBI has since become an affiliate company of JSR Life Sciences, a business unit of Tokyo-based JSR Corp.